Achieve Life Sciences (ACHV) Restructuring Costs (2010 - 2016)
Achieve Life Sciences' (ACHV) quarterly Restructuring Costs came in at -$431000.0 in Q3 2016, down 131.35% on a QoQ basis from $1.4 million in Q2 2016.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Restructuring Costs (2010 - 2016) Analysis & Trends
Achieve Life Sciences (ACHV) has 1 years of Restructuring Costs data on file, last reported at -$431000.0 in Q3 2016.
- Quarterly Restructuring Costs changed N/A year-over-year to -$431000.0 in Q3 2016, while the trailing twelve-month figure through Dec 2016 was $1.4 million (changed N/A YoY) and the FY2016 annual result came in at $1.4 million, changed N/A from the prior year.
- Restructuring Costs fell to -$431000.0 in Q3 2016, from $1.4 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $1.4 million in Q2 2016 to a low of -$431000.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2016 | -431,000.00 |
| Jun 30, 2016 | 1.38 Mn |
| Mar 31, 2016 | 431,000.00 |
| Dec 31, 2012 | -1.66 Mn |
| Sep 30, 2010 | 4.04 Mn |